Description: LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Home Page: www.cytrx.com
11726 San Vicente Boulevard
Los Angeles,
CA
90049
United States
Phone:
310 826 5648
Officers
| Name | Title |
|---|---|
| Mr. John Y. Caloz | CFO, Treasurer & Sr. VP |
| Dr. Stephen Snowdy Ph.D. | Chief Exec. Officer |
| Molly Carey Poarch | Global & U.S. Head of Corp. Communications |
| Ms. Molly Painter | Pres of USA and Head of Launch & Commercial Operations |
| Terri Stevens | Chief Bus. Officer |
| Ms. Cristina Newman | Corp. Sec. |
| Dr. Felix Kratz Ph.D. | Sr. VP, Drug Devel. |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.4775 |
| Price-to-Sales TTM: | 34.4758 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |